HEMCM42 antibodies
    41.
    发明授权
    HEMCM42 antibodies 有权
    HEMCM42抗体

    公开(公告)号:US07914789B2

    公开(公告)日:2011-03-29

    申请号:US11801040

    申请日:2007-05-07

    IPC分类号: A61K39/395

    CPC分类号: C07K14/47 A61K38/00 C07K16/00

    摘要: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

    摘要翻译: 本发明涉及含有编码这些蛋白质的基因的编码区的新的人分泌蛋白和分离的核酸。 还提供了用于产生人分泌蛋白质的载体,宿主细胞,抗体和重组方法。 本发明还涉及用于诊断和治疗与这些新型人分泌蛋白相关的病症的诊断和治疗方法。

    Method of inhibiting human G-protein chemokine receptor (CCR5) HDGNR10
    43.
    发明授权
    Method of inhibiting human G-protein chemokine receptor (CCR5) HDGNR10 有权
    抑制人G蛋白趋化因子受体(CCR5)HDGNR10的方法

    公开(公告)号:US07862818B2

    公开(公告)日:2011-01-04

    申请号:US11626244

    申请日:2007-01-23

    IPC分类号: A61K39/395 A61K31/00

    摘要: The present invention relates to a novel human protein called Human G-protein Chemokine Receptor (CCR5) HDGNR10, and isolated polynucleotides encoding this protein. The invention is also directed to human antibodies that bind Human G-protein Chemokine Receptor (CCR5) HDGNR10 and to polynucleotides encoding those antibodies. Also provided are vectors, host cells, antibodies, and recombinant methods for producing Human G-protein Chemokine Receptor (CCR5) HDGNR10 and human anti-Human G-protein Chemokine Receptor (CCR5) HDGNR10 antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to this novel human protein and these novel human antibodies.

    摘要翻译: 本发明涉及一种称为人G蛋白趋化因子受体(CCR5)HDGNR10的新型人类蛋白质,以及编码该蛋白质的分离的多核苷酸。 本发明还涉及结合人G蛋白趋化因子受体(CCR5)HDGNR10的人抗体和编码那些抗体的多核苷酸。 还提供了用于产生人G蛋白趋化因子受体(CCR5)HDGNR10和人抗人G蛋白趋化因子受体(CCR5)HDGNR10抗体的载体,宿主细胞,抗体和重组方法。 本发明还涉及用于诊断和治疗与该新型人蛋白质和这些新型人抗体相关的疾病,病症和/或病症的诊断和治疗方法。

    Albumin Fusion Proteins
    45.
    发明申请
    Albumin Fusion Proteins 审中-公开
    白蛋白融合蛋白

    公开(公告)号:US20100286048A1

    公开(公告)日:2010-11-11

    申请号:US12570397

    申请日:2009-09-30

    摘要: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

    摘要翻译: 本发明涵盖白蛋白融合蛋白。 编码本发明的白蛋白融合蛋白的核酸分子也包括在本发明中,载体含有这些核酸,用这些核酸载体转化的宿主细胞,以及制备本发明的白蛋白融合蛋白并使用这些核酸的方法 酸,载体和/或宿主细胞。 另外,本发明包括包含白蛋白融合蛋白的药物组合物以及使用本发明的白蛋白融合蛋白来治疗,预防或改善疾病,紊乱或病症的方法。

    Tumor necrosis factor-gamma
    46.
    发明授权
    Tumor necrosis factor-gamma 有权
    抗肿瘤坏死因子-γ的抗体

    公开(公告)号:US07820798B2

    公开(公告)日:2010-10-26

    申请号:US11837082

    申请日:2007-08-10

    摘要: Human TNF-gamma-alpha and TNF-gamma-beta polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing such polypeptides to inhibit cellular growth, for example in a tumor or cancer, for facilitating wound-healing, to provide resistance against infection, induce inflammatory activities, and stimulating the growth of certain cell types to treat diseases, for example restenosis. Also disclosed are diagnostic methods for detecting a mutation in the TNF-gamma-alpha and TNF-gamma-beta nucleic acid sequences or overexpression of the TNF-gamma-alpha and/or TNF-gamma-beta polypeptides. Antagonists against such polypeptides and their use as a therapeutic to treat cachexia, septic shock, cerebral malaria, inflammation, arthritis and graft-rejection are also disclosed.

    摘要翻译: 公开了人类TNF-γ-α和TNF-γ-β多肽和编码这种多肽的DNA(RNA)以及通过重组技术产生此类多肽的方法。 还公开了利用这些多肽抑制细胞生长的方法,例如在肿瘤或癌症中,用于促进伤口愈合,提供抗感染,诱导炎症活性和刺激某些细胞类型的生长以治疗疾病, 示例再狭窄。 还公开了用于检测TNF-γ-α和TNF-γ-β核酸序列中的突变或TNF-γ-α和/或TNF-γ-β多肽的过表达的诊断方法。 还公开了抗这些多肽的拮抗剂及其作为治疗性恶病质,败血性休克,脑疟疾,炎症,关节炎和移植排斥的治疗剂的用途。

    Antibodies that specifically bind to Reg IV
    48.
    发明授权
    Antibodies that specifically bind to Reg IV 失效
    特异性结合Reg IV的抗体

    公开(公告)号:US07763244B2

    公开(公告)日:2010-07-27

    申请号:US11583101

    申请日:2006-10-19

    申请人: Craig A. Rosen

    发明人: Craig A. Rosen

    IPC分类号: A61K39/395 C07K16/18

    摘要: The present invention relates to antibodies and related molecules that specifically bind to Reg IV. Such antibodies have uses, for example, in the prevention and treatment of gastrointestinal tract cancers, inflammatory bowel disorders, and diabetes. The invention also relates to nucleic acid molecules encoding anti-Reg IV antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially gastrointestinal tract cancers, inflammatory bowel disorders, and diabetes, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that specifically bind to Reg IV.

    摘要翻译: 本发明涉及特异性结合Reg IV的抗体和相关分子。 这样的抗体具有例如用于预防和治疗胃肠道癌症,炎症性肠病和糖尿病的用途。 本发明还涉及编码抗Reg IV抗体的核酸分子,含有这些核酸的载体和宿主细胞及其制备方法。 本发明涉及用于预防,检测,诊断,治疗或改善疾病或病症,特别是胃肠道癌症,炎症性肠病和糖尿病的方法和组合物,包括向动物,优选人类施用有效量的一种 或更多的与Reg IV特异性结合的抗体或其片段或变体,或相关分子。